Circ-Heart Fail: The effect of Tafamidis on the long-term survival of patients with transthyretin amyloid cardiomyopathy

Tafamidis (Fx1006A) is a dynamic stabilizer of transthyretin, which can inhibit amyloid cascade reaction

Recently, a research article published in Circ-Heart Fail, an authoritative journal in the cardiovascular field, reported the long-term efficacy data of Tafamidis in the treatment of patients with transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy patients who have completed the ATTR-ACT trial can participate in the long-term extended analysis (LTE), continue to use the same Tafamidis dose, or randomize (2:1) if they have received placebo treatment before 80 Or 20mg Tafamidis meglumine treatment

The median follow-up time in the Tafamidis group (n=176) and placebo group (n=177) were 58.

It can be seen that the survival rate of patients initially treated with Tafamidis in the ATTR-ACT trial is significantly higher than that of patients initially treated with placebo, which highlights the importance of early diagnosis and treatment for transthyretin amyloid cardiomyopathy

Original source:

Perry Elliott,et al.